Activation of mitochondrial apoptosis pathways in cutaneous squamous cell carcinoma cells by diclofenac/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w

Experimental Dermatology

Volumn 21, Issue 7, 2012, Pages 520-525

  Rodust, Paul M ^a,b   Fecker, Lothar F ^a   Stockfleth, Eggert ^a   Eberle, Jürgen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Actinic keratosis; Bcl 2 proteins; Diclofenac; Non steroidal anti inflammatory drugs; Prostaglandin E2

Indexed keywords

APOPTOSIS INDUCING FACTOR; CELECOXIB; CYCLOOXYGENASE 2; CYTOCHROME C; DICLOFENAC; HYALURONIC ACID; PROSTAGLANDIN E2; PROTEIN BAD; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN;

ACTINIC KERATOSIS; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CARCINOMA; UPREGULATION;

APOPTOSIS; APOPTOSIS INDUCING FACTOR; APOPTOSIS REGULATORY PROTEINS; BCL-ASSOCIATED DEATH PROTEIN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; CYTOCHROMES C; DICLOFENAC; DINOPROSTONE; DOWN-REGULATION; HUMANS; HYALURONIC ACID; MITOCHONDRIA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZOLES; SKIN NEOPLASMS; SULFONAMIDES; UP-REGULATION;

EID: 84863101809     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2012.01516.x     Document Type: Article

References (52)

1. Ulrich C, Busch J O, Meyer T et al. Br J Dermatol 2006: 155: 451-454.
2. Trakatelli M, Ulrich C, del M V, Euvrard S, Stockfleth E, Abeni D. Br J Dermatol 2007: 156 (Suppl 3): 1-7.
3. Stockfleth E, Ferrandiz C, Grob J J, Leigh I, Pehamberger H, Kerl H. Eur J Dermatol 2008: 18: 651-659.
4. Rowert-Huber J, Patel M J, Forschner T et al. Br J Dermatol 2007: 156 (Suppl 3): 8-12.
5. Hauschild A, Popp G, Stockfleth E et al. Exp Dermatol 2009: 18: 116-121.
6. Toll A, Salgado R, Yebenes M et al. Exp Dermatol 2010: 19: 151-153.
7. Eberle J, Fecker L F, Forschner T, Ulrich C, Rowert-Huber J, Stockfleth E. Br J Dermatol 2007: 156: 18-24.
8. Wrone-Smith T, Bergstrom J, Quevedo M E, Reddy V, Gutierrez-Steil C, Nickoloff B J. J Dermatol Sci 1999: 19: 53-67.
9. Russell J H, Ley T J. Annu Rev Immunol 2002: 20: 323-370.
10. Lavrik I, Golks A, Krammer P H. J Cell Sci 2005: 118: 265-267.
11. Eberle J, Fecker L F, Hossini A M, Kurbanov B M, Fechner H. Exp Dermatol 2008: 17: 1-11.
12. Fulda S, Debatin K M. Oncogene 2006: 25: 4798-4811.
13. Tait S W G, Green D R. Nat Rev Mol Cell Biol 2010: 11: 621-632.
14. Skyrlas A, Hantschke M, Passa V, Gaitanis G, Malamou-Mitsi V, Bassukas I D. Exp Dermatol 2011: 20: 674-676.
15. Hossini A M, Eberle J. Biochem Pharmacol 2008: 76: 1612-1619.
16. Chipuk J E, Moldoveanu T, Llambi F, Parsons M J, Green D R. Mol Cell 2010: 37: 299-310.
17. Eberle J, Kurbanov B M, Hossini A M, Trefzer U, Fecker L F. Drug Resist Updates 2007: 10: 218-234.
18. An K P, Athar M, Tang X W et al. Photochem Photobiol 2002: 76: 73-80.
19. Kuzbicki L, Lange D, Stanek-Widera A, Chwirot B W. Folia Histochem Cytobiol 2011: 49: 381-388.
20. Fecker L F, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. Br J Dermatol 2007: 156: 25-33.
21. Rodust P M, Stockfleth E, Ulrich C, Leverkus M, Eberle J. Br J Dermatol 2009: 161 (Suppl 3): 107-115.
22. Ulrich C, Johannsen A, Rowert-Huber J, Ulrich M, Sterry W, Stockfleth E. Eur J Dermatol 2010: 20: 482-488.
23. Pflugfelder A, Welter A K, Leiter U et al. J Eur Acad Dermatol Venereol 2012: 26: 48-53.
24. Fecker L F, Stockfleth E, Braun F K et al. J Invest Dermatol 2010: 130: 2098-2109.
25. Tilgen W, Boukamp P, Breitkreutz D et al. Cancer Res 1983: 43: 5995-6011.
26. Rheinwald J G, Beckett M A. Cancer Res 1981: 41: 1657-1663.
27. Riccardi C, Nicoletti I. Nat Protoc 2006: 1: 1458-1461.
28. Merk H F. Int J Dermatol 2007: 46: 12-18.
29. Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M. Int J Cell Biol 2010: 2010: 215158.
30. Wiswedel I, Grundmann J U, Boschmann M et al. J Invest Dermatol 2007: 127: 1794-1797.
31. Paz M L, Ferrari A, Weill F S, Leoni J, Maglio D H. Cytokine 2008: 44: 70-77.
32. Iglesias-Serret D, Pique M, Barragan M et al. Apoptosis 2010: 15: 219-229.
33. Rudner J, Elsaesser S J, Jendrossek V, Huber S M. Biochem Pharmacol 2011: 81: 32-42.
34. Gomez-Lechon M J, Ponsoda X, O'Connor E, Donato T, Castell J V, Jover R. Biochem Pharmacol 2003: 66: 2155-2167.
35. Agarwal S, Achari C, Praveen D, Roy K R, Reddy G V, Reddanna P. Exp Dermatol 2009: 18: 939-946.
36. Li H L, Zhu H, Xu C J, Yuan J Y. Cell 1998: 94: 491-501.
37. Liou J Y, Ghelani D, Yeh S, Wu K K. Cancer Res 2007: 67: 3185-3191.
38. Sitailo L A, Jerome-Morais A, Denning M F. J Invest Dermatol 2009: 129: 1351-1360.
39. Gillissen B, Wendt J, Richter A et al. J Cell Biol 2010: 188: 851-862.
40. Chen W J, Bai L, Wang X, Xu S L, Belinsky S A, Lin Y. Mol Pharmacol 2010: 77: 416-423.
41. Grosch S, Maier T J, Schiffmann S, Geisslinger G. J Natl Cancer Inst 2006: 98: 736-747.
42. Yan W, Samson M, Jegou B, Toppari J. Mol Endocrinol 2000: 14: 682-699.
43. Nam D H, Park K, Park C et al. Oncol Rep 2004: 11: 263-268.
44. Dandekar D S, Lopez M, Carey R I, Lokeshwar B L. Int J Cancer 2005: 115: 484-492.
45. Wun T, McKnight H, Tuscano J M. Leuk Res 2004: 28: 179-190.
46. Greenhough A, Wallam C A, Hicks D J, Moorghen M, Williams A C, Paraskeva C. Oncogene 2010: 29: 3398-3410.
47. Riendeau D, Percival M D, Brideau C et al. J Pharmacol Exp Ther 2001: 296: 558-566.
48. Yamazaki T, Muramoto M, Oe T et al. Neuropharmacology 2006: 50: 558-567.
49. Czembirek C, Eder-Czembirek C, Erovic B M et al. Strahlenther Onkol 2009: 185: 310-317.
50. Braun F K, Al-Yacoub N, Plötz M, Möbs M, Sterry W, Eberle J. J Invest Dermatol 2011: 132: 429-439.
51. Fredriksson L, Herpers B, Benedetti G et al. Hepatology 2011: 53: 2027-2041.
52. Singh R, Cadeddu R P, Frobel J et al. Apoptosis 2011: 16: 889-901.